Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07024641 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection
A Phase 1 study of Hepatitis B Virus Infection, sponsored by GigaGen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 16
- Study locations
NCT07024641 is a Phase 1 study of Hepatitis B Virus Infection that is actively recruiting participants, run by GigaGen. The registered enrollment target is 48 participants. The trial reports 16 study locations across 12 states.
The verdict
NCT07024641, a Phase 1 study of Hepatitis B Virus Infection, is actively recruiting participants, sponsored by GigaGen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 16
- Study locations
Study Summary
The primary purpose of this study is to assess the safety and tolerability of single and multiple intravenous (IV) doses of GIGA-2339 in participants with chronic Hepatitis B Virus (HBV) infection.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GIGA-2339
Study Locations (16)
California
- Grifols Investigative site - Huntington Beach
- Grifols Investigative site - Lake Forest
- Grifols Investigative site - Long Beach
- Grifols Investigative site - Oakland
Texas
- Grifols Investigative site - San Antonio
- Grifols Investigative site - Webster
Arizona
- Grifols Investigative site - Chandler
Georgia
- Grifols Investigative Site - Peachtree Corners
Iowa
- Grifols Investigative Site - Iowa City
Kansas
- Grifols Investigative Site - Lenexa
Maryland
- Grifols Investigative site - Baltimore
Virginia
- Grifols Investigative site - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2024-11-13 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07024641
The ClinicalTrials.gov registry entry for NCT07024641 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GigaGen, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatitis B Virus Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07024641 reports 16 study locations spanning 12 distinct geographic areas - top geographies include California, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT07024641 about?
NCT07024641 is a clinical study titled "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection". The primary purpose of this study is to assess the safety and tolerability of single and multiple intravenous (IV) doses of GIGA-2339 in participants with chronic Hepatitis B Virus (HBV) infection.
What is the current status of trial NCT07024641?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2024-11-13. Estimated completion is 2027-09.
What conditions does trial NCT07024641 study?
This clinical trial studies the following conditions: Hepatitis B Virus Infection.
What interventions are being tested in trial NCT07024641?
The interventions under investigation include: Placebo (DRUG), GIGA-2339 (DRUG).
Who is sponsoring clinical trial NCT07024641?
This trial is sponsored by GigaGen, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07024641 being conducted?
This trial has 16 study locations across Arizona, California, Georgia, Iowa, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.